Treeline is preparing to enter the public market through a reverse merger with microfluidics company Standard BioTools, marking a major move for the biotechnology startup. The deal, announced Monday, positions Treeline as one of the most closely watched biotech firms entering public markets in 2026.
Under the agreement, shareholders of Standard BioTools will own approximately 15.5% of the newly combined company, while Treeline’s investors will control the remaining 84.5%. The structure gives Treeline a strong ownership position as it transitions into a publicly traded company.
The transaction also includes contingent value rights for Standard shareholders tied to proceeds from potential sales involving Standard’s pre-merger assets. This adds another layer of value for existing investors as the company restructures around Treeline’s pipeline.
Treeline aims to enter the public market with nearly $900 million in cash, strengthening its ability to accelerate clinical development and pipeline growth.
Treeline’s Reverse Merger Strengthens Public Market Entry
Treeline is led by Josh Bilenker, a respected biotech executive best known for leading Loxo Oncology before its $8 billion acquisition by Eli Lilly in 2019. Following that deal, Bilenker briefly led Lilly’s cancer drug division before focusing on building Treeline.
Since its launch, Treeline has secured more than $1 billion in private funding. The company has focused on developing both in-licensed and internally discovered therapies targeting difficult-to-treat cancers.
Its strategy centers on identifying promising biological targets and advancing innovative drug candidates through early-stage development. This approach has positioned Treeline as a high-potential player in the oncology sector.
Leadership continuity remains a key strength for the company, with Bilenker continuing as CEO alongside Chief Scientific Officer Jeff Engelman and Chief Financial Officer Spencer Smith.
Treeline Builds a Strong Oncology Drug Pipeline
Treeline currently has four publicly disclosed drug programs, all focused on cancer treatment. These programs include therapies designed to inhibit or degrade proteins that tumors rely on for growth and survival.
One of its lead candidates, TLN-121, targets BCL6, a protein that helps lymphoma cells evade the immune system. The drug is currently in early-stage clinical testing and may eventually be used in combination therapies.
Treeline licensed TLN-254 from Hengrui Pharmaceuticals in 2023. The therapy targets EZH2, a gene often linked to cancer progression, and doctors in China already use it to treat patients with relapsed or refractory peripheral T-cell lymphoma.
Treeline is also advancing TLN-372, a drug designed for pan-KRAS inhibition. KRAS remains one of the most challenging targets in oncology, and the company believes its broader inhibition strategy could offer meaningful therapeutic advantages.
Read : How 4 Minutes of Daily Exercise Benefits Older Adults
Investors Watch Treeline’s Growth and Market Potential
A fourth experimental therapy targeting BCL-XL could begin Phase 1 testing later this year, while several undisclosed programs are also in development. Together, these assets create a catalyst-rich pipeline with multiple growth opportunities.
According to Bilenker, Treeline’s long-term vision is centered on repeatable scientific execution. The company aims to build a reputation for selecting high-value targets, developing strong candidates, and making disciplined clinical decisions.
Standard BioTools CEO Michael Egholm described the merger as an opportunity to provide shareholders with exposure to a high-growth biotech portfolio capable of generating both short-term and long-term value.
Despite the strategic rationale, investor reaction was mixed, with Standard BioTools shares falling 20% following the announcement. If the merger closes in the second half of 2026, the combined company will trade on the Nasdaq under the ticker symbol “TRLN.”
